New pill targets genetic driver in Tough-to-Treat liver cancer
Disease control
Not yet recruiting
This study is for adults with advanced bile duct cancer that has a specific genetic change (FGFR2) and has worsened after initial treatment. It compares a new targeted pill called TT-00420 to standard chemotherapy to see which is better at controlling the cancer and is safer. The…
Phase: PHASE3 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC